Evolent Health, Inc. (EVH)
NYSE: EVH · Real-Time Price · USD
7.46
-0.54 (-6.81%)
May 22, 2025, 12:48 PM - Market open
Evolent Health Revenue
Evolent Health had revenue of $483.65M in the quarter ending March 31, 2025, a decrease of -24.39%. This brings the company's revenue in the last twelve months to $2.40B, up 10.24% year-over-year. In the year 2024, Evolent Health had annual revenue of $2.55B with 30.09% growth.
Revenue (ttm)
$2.40B
Revenue Growth
+10.24%
P/S Ratio
0.38
Revenue / Employee
$533,053
Employees
4,500
Market Cap
863.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.55B | 590.85M | 30.09% |
| Dec 31, 2023 | 1.96B | 611.88M | 45.26% |
| Dec 31, 2022 | 1.35B | 444.06M | 48.91% |
| Dec 31, 2021 | 907.96M | -16.68M | -1.80% |
| Dec 31, 2020 | 924.64M | 237.52M | 34.57% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
EVH News
- 12 days ago - Evolent Health, Inc. (EVH) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Evolent Announces First Quarter 2025 Results - PRNewsWire
- 4 weeks ago - Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors - PRNewsWire
- 5 weeks ago - Evolent program achieves 20% reduction in use of low-value oncology regimens - PRNewsWire
- 5 weeks ago - Evolent To Release First Quarter 2025 Financial Results on Thursday, May 8, 2025 - PRNewsWire
- 3 months ago - Evolent Health, Inc. (EVH) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Evolent Announces Fourth Quarter and Full Year 2024 Results - PRNewsWire
- 3 months ago - Evolent Health Announces Changes to Board of Directors - PRNewsWire